ArticleBioMed research international2015
Identification of Novel Potential Vaccine Candidates against Tuberculosis Based on Reverse Vaccinology.
Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 91 citations in OpenAlex.
- Structural Characterization and Functional Annotation of Hypothetical Proteins in the Multidrug-Resistant Strains ofBioMed research international · 2026Article
- Reverse vaccinology-based identification of immunogenic membrane proteins from zoonotic multidrug-resistant Proteus vulgaris: a one health approach to cross-species vaccine development.BMC veterinary research · 2025Article
- Immunoinformatics analysis of the proteins MPT83 and MPT51 to design a possible chimeric vaccine against Mycobacterium tuberculosis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- PPE50 variants as novel phylogeographic signatures of host-pathogen co-evolution in tuberculosis.Communications biology · 2025Article
- Article
- Article
- Characterization of proteins present in the biofilm matrix and outer membrane vesicles ofmBio · 2025Article
- Interred mechanisms of resistance and host immune evasion revealed through network-connectivity analysis ofmSystems · 2025Article
- Molecular dynamics simulation shows enhanced stability in scaffold-based macromolecule, designed by protein engineering: a novel methodology adapted for converting Mtb Ag85A to a multi-epitope vaccine.Journal of molecular modeling · 2025Article
- One Health Approach to the Computational Design of a Lipoprotein-Based Multi-Epitope Vaccine Against Human and Livestock Tuberculosis.International journal of molecular sciences · 2025Article
- Article
- Immunoinformatics Design of a Multiepitope Vaccine (MEV) TargetingPathogens (Basel, Switzerland) · 2024Article
- Immunopeptidomics ofBiology · 2024Article
- Enhancing tuberculosis vaccine development: a deconvolution neural network approach for multi-epitope prediction.Scientific reports · 2024Article
- Design of a Multi-Epitope Vaccine against Tuberculosis fromMicroorganisms · 2023Article
- In silico prediction and expression analysis of vaccine candidate genes of Campylobacter jejuni.Poultry science · 2023Article
- Advances in protein subunit vaccines against tuberculosis.Frontiers in immunology · 2023Review
- Advances in computational frameworks in the fight against TB: The way forward.Frontiers in pharmacology · 2023Review
- Design of a multi-epitope vaccine against six Nocardia species based on reverse vaccinology combined with immunoinformatics.Frontiers in immunology · 2023Article
- Recent Advances in Genomics-Based Approaches for the Development of Intracellular Bacterial Pathogen Vaccines.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is a chronic infectious disease, considered as the second leading cause of death worldwide, caused by Mycobacterium tuberculosis. The limited efficacy of the bacillus Calmette-Guérin (BCG) vaccine against pulmonary TB and the emergence of multidrug-resistant TB warrants the need for more efficacious vaccines. Reverse vaccinology uses the entire proteome of a pathogen to select the best vaccine antigens by in silico approaches. M. tuberculosis H37Rv proteome was analyzed with NERVE (New Enhanced Reverse Vaccinology Environment) prediction software to identify potential vaccine targets; these 331 proteins were further analyzed with VaxiJen for the determination of their antigenicity value. Only candidates with values ≥0.5 of antigenicity and 50% of adhesin probability and without homology with human proteins or transmembrane regions were selected, resulting in 73 antigens. These proteins were grouped by families in seven groups and analyzed by amino acid sequence alignments, selecting 16 representative proteins. For each candidate, a search of the literature and protein analysis with different bioinformatics tools, as well as a simulation of the immune response, was conducted. Finally, we selected six novel vaccine candidates, EsxL, PE26, PPE65, PE_PGRS49, PBP1, and Erp, from M. tuberculosis that can be used to improve or design new TB vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.